Next-generation sequencing in routine brain tumor diagnostics enables an integrated diagnosis and identifies actionable targets
- 2.7k Downloads
With the number of prognostic and predictive genetic markers in neuro-oncology steadily growing, the need for comprehensive molecular analysis of neuropathology samples has vastly increased. We therefore developed a customized enrichment/hybrid-capture-based next-generation sequencing (NGS) gene panel comprising the entire coding and selected intronic and promoter regions of 130 genes recurrently altered in brain tumors, allowing for the detection of single nucleotide variations, fusions, and copy number aberrations. Optimization of probe design, library generation and sequencing conditions on 150 samples resulted in a 5-workday routine workflow from the formalin-fixed paraffin-embedded sample to neuropathological report. This protocol was applied to 79 retrospective cases with established molecular aberrations for validation and 71 prospective cases for discovery of potential therapeutic targets. Concordance of NGS compared to established, single biomarker methods was 98.0 %, with discrepancies resulting from one case where a TERT promoter mutation was not called by NGS and three ATRX mutations not being detected by Sanger sequencing. Importantly, in samples with low tumor cell content, NGS was able to identify mutant alleles that were not detectable by traditional methods. Information derived from NGS data identified potential targets for experimental therapy in 37/47 (79 %) glioblastomas, 9/10 (90 %) pilocytic astrocytomas, and 5/14 (36 %) medulloblastomas in the prospective target discovery cohort. In conclusion, we present the settings for high-throughput, adaptive next-generation sequencing in routine neuropathology diagnostics. Such an approach will likely become highly valuable in the near future for treatment decision making, as more therapeutic targets emerge and genetic information enters the classification of brain tumors.
KeywordsMedulloblastoma Pilocytic Astrocytoma FFPE Tissue Copy Number Aberration Diffuse Glioma
This study was supported by the German Cancer Aid (110670) and by a PostDoc fellowship of the Medical Faculty Heidelberg to FS. We also thank the DKFZ-Heidelberg Center for Personalized Oncology (DKFZ-HIPO) for funding through HIPO_036 and HIPO_057.
- 1.BCL to fastq conversion. https://www.support.illumina.com/content/dam/illumina-support/documents/documentation/software_documentation/bcl2fastq/bcl2fastq2-v216-Software-Guide-15051736-E.pdf. Accessed 8 Oct 2015
- 2.Fastqc. http://www.bioinformatics.babraham.ac.uk/projects/fastqc/. Accessed 8 Oct 2015
- 3.Picard duplicate removal. http://broadinstitute.github.io/picard/. Accessed 8 Oct 2015
- 4.SAMtools. https://samtools.github.io/hts-specs/SAMv1.pdf. Accessed 8 Oct 2015
- 5.SAMtools mpileup. http://www.samtools.sourceforge.net/mpileup.shtml. Accessed 8 Oct 2015
- 6.SAMtools vcf. http://samtools.github.io/hts-specs/VCFv4.2.pdf. Accessed 8 Oct 2015
- 13.Hovestadt V, Zapatka M. Enhanced copy-number variation analysis using Illumina 450 k methylation arrays. https://www.bioconductor.org/packages/release/bioc/html/conumee.html. Accessed 8 Oct 2015
- 28.Reuss DE, Sahm F, Schrimpf D, Wiestler B, Capper D, Koelsche C et al (2015) ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an “integrated” diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma. Acta Neuropathol 129(1):133–146CrossRefPubMedGoogle Scholar
- 32.Serizawa M, Yokota T, Hosokawa A, Kusafuka K, Sugiyama T, Tsubosa Y et al (2015) The efficacy of uracil DNA glycosylase pretreatment in amplicon-based massively parallel sequencing with DNA extracted from archived formalin-fixed paraffin-embedded esophageal cancer tissues. Cancer Genet 208(9):415–427CrossRefPubMedGoogle Scholar